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Setup for human sera MALDI profiling: The
case of rhEPO treatment
The implementation of high-throughput technologies based on qualitative and quanti-
tative methodologies for the characterization of complex protein mixtures is increasingly
required in clinical laboratories. MALDI profiling is a robust and sensitive technology
although the serum high dynamic range imposes a major limitation hampering the
identification of less abundant species decreasing the quality of MALDI profiling. A
setup to improve these parameters has been performed for recombinant human
erythropoietin (rhEPO) monitoring in serum, analyzing the effects of two commercially
available columns (MARS Hu7 and Hu14) for immunodepletion, and two matrices (a-
cyano-4-hydroxycinnamic acid and 20,40-dihydroxyacetophenone) for peak quality
improvement. The immunodepletion capability of both columns was determined by 2-D
DIGE, which precisely revealed the efficacy of Hu14 in protein removal and the serum
dynamic range decrement. In addition, the type of matrix, the sample dilution, and the
efficacy of optimized parameters were used for serum profiling of ten healthy subjects
before and after rhEPO treatment. The principal component analysis indicates that a
combination of Hu14 column and 20,40-dihydroxyacetophenone matrix increases data
quality allowing the discrimination between treated and untreated samples, making
serum MALDI profiling suitable for clinical monitoring of rhEPO.
Keywords:
EPO / Immunodepletion / MALDI profiling / Serum / 2-D differential gel
electrophoresis DOI 10.1002/elps.201100134
1 Introduction
More and more proteomic approaches are imposing
themselves in clinical studies for qualitative and quantitative
investigation related to protein and peptide expression
profiles from body fluids and tissue extracts [1]. Moreover,
to make these methodologies suitable for clinical practice, it
is necessary to isolate and quantify proteins from biological
fluids. Currently, proteomic analysis of biological fluids is
one of the most promising approaches in biomarker
discovery [2]. In particular, serum, the most relevant source
of biomarkers [3, 4], is increasingly utilized in clinical
proteomic studies [4, 5].
Serum profiling by using surfaced-enhanced laser
desorption ionization (SELDI) was utilized to investigate
pathological status, particularly breast cancer, for the
analysis of low-molecular-weight proteins [6–8]. Surfaced-
enhanced laser desorption ionization opened a new avenue
in the application of laser desorbed based fingerprinting for
clinical diagnosis providing spectra, as fingerprints. The
possibility of identifying peaks adopting advanced instru-
mentation makes MALDI profiling more robust and sensi-
tive [9] due to its high throughput and reliability in protein
detection [10]. Both, protein profiles and the single identified
protein, can provide disease-specific protein patterns or
biomarkers after clinical validation. Despite the strong
potential of MALDI, the main issue to face remains the
serum dynamic range (i.e. the range of serum protein
concentrations from high- to low-abundance proteins,
estimated in ten orders of magnitude [11]) which encom-
passes eight orders of magnitude the capacity of the mass
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spectrometer to discriminate species in complex mixtures
[12–15] preventing the detection of biomarkers from pico-
gram to femtogram levels, such as prostate specific antigen
(PSA) or interleukins, leaving undisclosed a large number of
proteins and peptides. So far, to overcome this issue, an
adequate fractionation step prior proteomic analysis is
mandatory in order to remove high-abundant components.
Several prefractionation methodologies have been intro-
duced such as ultracentrifugation [4, 16], solid-phase
extraction (SPE) columns [17–21], size fractionation [22],
derivatized beads [23, 24], combinatorial peptide ligand
libraries [25], and specific enrichment techniques [26–29].
Moreover, the high cost, the scarce selectivity, or long
operation times, impose the development of new depletion
systems based on multiple affinity columns [30, 31]. The
latter are characterized by the presence of specific antibodies
derivatized columns which specifically and selectively
deplete a number of high-abundant proteins in serum plus
their proteolytic products and molecular forms [32–37]. The
selection of a methodological approach providing optimal
reduction of the serum dynamic range with high reprodu-
cibility represents a critical point for the translation of
MALDI serum profiling to clinical laboratories. This study
puts forward the development of a robust platform to
analyze the effects of recombinant human erythropoietin
(rhEPO) treatment in human sera by MALDI.
Erythropoietin is a glycoprotein hormone, mainly
secreted by the kidney that, by stimulating red blood cell
production, increases oxygenation levels in tissues [38].
The recombinant form of EPO (rhEPO) is largely
utilized in patients affected by severe anemia and in the
treatment of pathologies associated with low oxygen levels in
blood [39, 40]. Furthermore, because of its capability to
increase physical performance, this hormone is one
of the most used doping agents. The use of rhEPO easily
increases red blood cell mass compared with homologous/
autologous blood transfusion. For this reason, rhEPO
is on the list of prohibited substances of International
Olympic Committee (IOC) and World Anti-Doping
Agency (WADA) [41]. In a previous study on male volun-
teers [42], rhEPO administration effectively increased
erythropoiesis, hematocrit, hemoglobin, and iron mobiliza-
tion; therefore, a number of changes in serum profile are
expected. Due to the short half-life, detection of rhEPO is
associated to its assumption modality and available tests can
reveal only chronic and/or massive assumption [43];
hence, the development of tests for monitoring rhEPO and
proteins or peptides associated to its intake remains of great
interest both for clinical purposes and for antidoping in
sport practice.
In this context, the aim of the present study is to
investigate the effects of different levels of immunodeple-
tion on dynamic range, to select the type of matrix
and deposition and to standardize the methodology for
implementing MALDI profiling for the analysis of human
serum after treatment of healthy human subjects with
rhEPO.
2 Materials and methods
2.1 Chemicals
ACN, trifluoroacetic acid, water, citric acid, L-lysine,
iodoacetamide, glycerol, PMSF, and ammonium bicarbo-
nate (AMBIC) were from Sigma-Aldrich (Milan, Italy) and
are of the highest purity available; buffers A and B for
immunodepletion were from Agilent Technologies (Palo
Alto, CA, USA). CHAPS, tris[hydroxymethyl] aminoethane
(Tris), SDS, bromophenol blue (BBF), agarose, urea,
thiourea, dithiothreitol (DTT), TEMED, methylenebisacryla-
mide, acrylamide, low-molecular-weight marker, Deep
Purple, CyDyes, nonlinear IPG strips, pH gradient 3-10
(18 cm long), and IPG buffer, pH 3–10, were from GE
Healthcare (Uppsala, Sweden). a-Cyano-4-hydroxycinnamic
acid (CHCA), 20,40-dihydroxyacetophenone (DHAP), and
peptide calibration standard mixture were from Bruker
Daltonics (Bremen, Germany); trypsin was purchased from
Promega (Madison, WI, USA) and SYPRO Ruby from
Molecular Probes (Eugene, OR, USA).
2.2 Sample collection
2.2.1 Immunodepletion and MALDI profiling setup
Blood samples were obtained from three healthy volunteer
male subjects and divided in two aliquots, for serum and
plasma collection, respectively. The first aliquot was
collected in vacutainer tubes placed at 141C for 15 min
until clotted, then centrifuged for 10 min at 2200 g at
141C and stored at 801C. The second was collected
in heparin vacutainer tubes, centrifuged (15 min, 2000 g,
141C), and stored at 801C until use.
2.2.2 rhEPO treatment
Sera were obtained from ten healthy young male volunteers.
The treatment protocol consisted of epoetin b (NeoRecor-
mon, Roche, Mannheim, Germany) subcutaneous injection
once every other day for 2 wks, and then once a week in the
third and fourth weeks. The measurements consisted of
blood samples taken from a forearm vein during supine rest
at baseline (control samples) and on days 2, 4, 6, 8, and 28 of
rhEPO treatment. EPO levels were assessed by enzyme-
linked immunoabsorbent assay (ELISA) kit (R&D Systems,
Minneapolis, MN, USA). Sera and plasma were obtained as
described previously [42].
2.3 Immunodepletion
Sera and plasma were thawed on ice for immunodepletion
by using Agilent multiple affinity removal system (MARS)
kit (Agilent Technologies). The columns Human 7 (Hu7)
and Human 14 (Hu14) were installed onto an Agilent 1200
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Series HPLC (Agilent Technologies). In total, 40 mL of each
sample were diluted fourfold in buffer A and centrifuged
with 0.22 mm filters (Cellulose acetate Spin-X, Corning, NY,
USA) to remove any cells and debris. After this process, the
samples were immunodepleted by MARS columns
4.6 50mm both Hu7 and Hu14 as recommended by the
manufacturers. Low-abundance protein (LAP) and high-
abundance protein (HAP) fractions were eluted in buffer A
and buffer B, respectively. Subsequently, each fraction was
quantified by BCA (BiCinchoninic Acid) assay (Pierce
Chemical, Rockford, IL, USA) and desalted by an mRP-
C18 column (Agilent Technologies) in an Agilent 1200
Series HPLC and eluted in 0.1%TFA in ACN; the
reproducibility was estimated by comparing ten chromato-
graphic peak areas per sample.
2.4 SDS-PAGE
After dilution in 2 loading buffer (125 mM Tris, 4% SDS,
10% glycerol, 130 mM DTT, BBF in traces), 5 mg of
crude, Hu7 depleted, and Hu14 depleted sera were loaded
twice to see the reproducibility of immunodepletion
techniques. Electrophoresis was carried out in a discontin-
uous buffer system with a 4% T stacking gel, pH 6.8, and a
15% T, pH 8.8 running gel. The gel was stained with
SYPRO Ruby and scanned with Typhoon laser scanner 9200
(GE Healthcare) at 532 nm excitation with a 610 nm band
pass emission filter. For protein identification, the band of
interest was excised from gel and subjected to in situ
hydrolysis.
2.5 Protein labeling
After immunodepletion, three serum samples were
concentrated with vacuum centrifuge (Concentrator 5301,
Eppendorf AG, Hamburg, Germany) and proteins were
selectively precipitated using PlusOne 2-D Clean Up kit (GE
Healthcare), to remove nonproteinaceous material, and
resuspended in lysis buffer (7 M urea, 2 M thiourea, 4%
CHAPS, 30 mM Tris, and 1mM PMSF). Protein concentra-
tion was determined using PlusOne 2-D Quant kit (GE
Healthcare). Briefly, 50 mg from each immunodepletion type
were labeled with 400 pmol Cy5 dye, whereas the internal
standard, generated by pooling together an aliquot of Hu7
and Hu14 serum, was labeled with 400 pmol Cy3 dye. The
minimal labeling was performed according to the manu-
facturer’s recommendations by incubating samples on ice in
the dark for 30 min. The labeling reaction was quenched
with 1 mL L-lysine 10 mM on ice for 10 min in the dark.
The three samples were pooled prior to the 2-DE analysis.
The ‘‘two dyes’’ protocol was adopted: the present experi-
mental design was performed by image acquisition with a
two laser scanner, Typhoon 9200, and the combination of
Cy3:Cy5, due to the labeling efficiency and reliability
compared with other dye combination, as described
previously [44–47]. Moreover, the use of the two dyes and
the manufacturer’s dye/protein ratio make the dye swap
unnecessary since all samples undergoing the statistical
analysis had been labeled with the same dye (Cy5) and
were normalized against the same internal standard (labeled
with Cy3).
2.6 2-D differential gel electrophoresis
Before IEF, Cy samples were resuspended in 2 sample
buffer containing 130mM DTT and 2% v/v IPG buffer.
Individual samples (40 mg) were combined with an equal
amount of internal standard; rehydratation buffer (7 M urea,
2 M thiourea, 2% CHAPS, 65 mM DTT, 0.5% IPG buffer,
pH 3.5–9.5, and BBF in traces) was added to a final volume
of 350 mL. Proteins from pooled samples were separated by
2-DE utilizing a 18 cm pH 3–10 nonlinear (NL) gradient IPG
strips by applying the following IEF voltage steps: 200 V
(2 h), 500 V (1 h), 1000 V (1 h), 2000 V (30min), 3000 V
(30 min), gradient 3000–8000 V (5 h), 8000 V until 65 000
VhT. IEF was performed using an IPGphor electrophoresis
unit (GE Healthcare). At the completion of the focusing
process, IEF strips were equilibrated in an SDS-reducing
buffer (6 M urea, 2% SDS, 20% glycerol, 375 mM Tris-HCl,
pH 8.8, 65 mM DTT) for 15 min, and then alkylated for
8 min in the same buffer containing 135mM iodoacetamide
instead of DTT. Second dimension was carried out in
(20 25 cm), 12% T, 2.5% C, constant concentration,
polyacrylamide gels at 201C, and 15mA per gel using the
Ettan Dalt II system (GE Healthcare).
2.7 Image acquisition and analysis
CyDye-labeled gels were visualized using a Typhoon 9200
laser scanner (GE Healthcare). Excitation and emission
wavelengths were chosen according to the manufacturer’s
recommendations (532 and 633 nm laser beams; 580 and
670 nm emission filters). Spot detection was performed
using DeCyder DIA module v. 6.5 (Difference In-gel
Analysis, GE Healthcare). Filters parameters were set as
follows: slope 1.2, minimal area cutoff 300, and peak height
14. The DeCyder BVA module v. 6.5 (Biological Variation
Analysis, GE Healthcare) was employed for inter-gel protein
spot matching, whereas statistical analysis was performed
using DeCyder EDA module v. 1.0 (Extended Data Analysis,
GE Healthcare). Statistically significant differences were
computed by Student’s t-test, the significance level was set at
po0.01. False discovery rate (FDR) was applied as multiple
test correction in order to keep the overall error rate as lower
as possible and only spots common to all replicates were
taken into consideration.
In order to indicate how many spots have a certain
abundance, normalized volumes (Cy5/Cy3) both for Hu7
and for Hu14 spots were downloaded by DeCyder and mean
values calculated for each spot. Subsequently seven
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normalized volume ranges were considered (0–1, 1–5, 5–10,
10–20, 20–50, 50–100, and above 100, respectively) for each
immunodepletion type and the number of spots into each
range was calculated and indicated in y-axis.
2.8 Protein identification by MS
For protein identification, semi-preparative gels were
performed: gels were loaded with unlabelled Hu7 and
Hu14 columns immunodepleted samples, respectively
(400 mg per strip), and proteins were separated as described
for analytical gels. After 2-DE, gels were stained with Deep
Purple total fluorescent stain (5 mL/L) following the
manufacturer’s recommendations. Image acquisition was
performed by Typhoon 9200 laser scanner (excitation
wavelength of 532 nm and emission wavelength filter of
560 nm). Spots were gel excised by means of the Ettan spot
picker robotic system (GE Healthcare) and digested with
30 mL of 5 ng/mL trypsin dissolved in 10 mM AMBIC at 371C
overnight. Released peptides underwent RP chromatogra-
phy using Zip-Tip C18 micro (Millipore, Bedford, MA, USA)
and eluted with 50%ACN/0.1%TFA. One microliter of
peptides mixture was spotted onto the sample plate of an
Ultraflex III MALDI-ToF/ToF (Bruker Daltonics) mass
spectrometer; an equal volume of 10 mg/mL CHCA matrix
dissolved in 70% ACN/30% 50mM citric acid was applied
and spots were air dried at room temperature. MS
proceeded with an accelerating voltage of 25 kV and spectra
were externally calibrated using Peptide Calibration Stan-
dard mixture; 1000 laser shots were taken per spectrum.
Proteins were identified by comparing digest peaks with a
computer-generated database of tryptic peptides from
known proteins using in-house MASCOT 2.2, which utilizes
a robust probabilistic scoring algorithm. Search was carried
out by correlation of uninterpreted spectra to Homo sapiens
entries in NCBInr 20100918 (National Center for Biotech-
nology Information non redundant) Database (11 823 178
sequences; 4 040 378 175 residues). With regard to
MASCOT parameters, one missed cleavage per peptide
was allowed, carbamidomethylation, as fixed modification,
and methionine oxidation, as variable modification, no mass
and pI constraints were set. Peptide mass tolerance was set
at 30 ppm. In cases where this approach was unsuccessful,
additional searches were performed using ESI MS/MS.
Tandem electrospray mass spectra were recorded using a
HCT Ultra mass spectrometer (Bruker Daltonics) interfaced
to a MDLC (MultiDimensional Liquid Chromatography)
capillary chromatograph (GE Healthcare). The samples were
dissolved in 0.1% aqueous formic acid, injected onto a
0.075 150 mm Zorbax 300SB-C18 column (Agilent Tech-
nologies), and eluted with an ACN/0.1% formic acid
gradient. The capillary voltage was set to 1600 V, and
data-dependent MS/MS acquisitions were performed on
precursors with charge states of 2, 3, or 4 over a survey mass
range of 300–1500; the collision gas was helium. Proteins
were identified by correlation of uninterpreted tandem mass
spectra to H. sapiens entries in NCBInr 20100918, using in-
house MASCOT 2.2 software. No mass and pI constraints
were applied. One missed cleavage per peptide was allowed,
and the fragment ion tolerance window was set to 0.3 Da.
Carbamidomethylation of cysteine was set as fixed modifica-
tion, whereas methionine oxidation was fixed as variable
modification.
2.9 Matrix preparation
After immunodepletion, samples were desalted, quantitated,
lyophilized, and resuspended in 0.1% TFA. Two different
matrices were tested and different solutions were
prepared: CHCA and DHAP (Table 1). Each solution was
ready made, sonicated for 15 min, and the supernatant
recovered.
As regards CHCA matrix, sample and matrix were
mixed and ten replicates of 1 mL were spotted onto the
AnchorChip target (600–384 target, Bruker Daltonics) and
dried at room temperature.
For DHAP matrix: the sample, matrix, and 2%TFA were
mixed as summarized in Table 1 and ten replicates of 1 mL
of the protein solution were spotted onto the AnchorChip
target and let to dry at room temperature.
2.10 MALDI profiling
Spectra were acquired in linear positive modality using an
Ultraflex III mass spectrometer equipped with Smartbeam
laser (frequency of 100 Hz, Bruker Daltonics), Flex Control
software v. 3.3, and Flex Analysis software v.3.3 (Bruker
Daltonics). Spectrometer settings were ion source 1, 25 kV;
ion source 2, 23.5 kV; lens, 6.3 kV; deflection; mass
suppression up to m/z 800; pulsed ion extraction, 100 ns;
detector gain voltage, 1798 V; electronic gain, 50 mV/full
scale; sample rate, 1 GS/s; and laser attenuator offset, 80%.
Spectra were collected using an automatic software,
AutoXecute (Bruker Daltonics), whose parameters were the
following: fuzzy control, off; laser power, 60%; total laser
shots, 1000; random walk movement (20 shots per raster
spot).
Mass spectra were analyzed by ClinProTools software
v.2.2 (Bruker Daltonics) using the following spectra
Table 1. Matrices and sample preparation for MALDI profiling
analysis
Matrix Working solutions Ratio
CHCA 0.3 mL/mL in 1:2 acetone:ethanol 1:1 (Sample/matrix)
1:4 (Sample/matrix)
1:10 (Sample/matrix)
DHAP 15 mg/mL in 3:1
ethanol:diammonium
hydrogen citrate
1:1:1 (2% TFA:sample:matrix)
2:2:1 (2% TFA: sample:matrix)
1:1:2 (2% TFA: sample:matrix)
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preparation parameters: 800 resolution, Top Hat Baseline,
10% minimal baseline width, Savitsky–Golay smoothing.
ClinProTools’ statistics was performed by Wilcoxon’s t-test
(significance level for p-valueo0.05) through which a list of
peaks was generated. The peaks were sorted along the
statistical differences between selected classes (e.g. healthy
controls and drug treatment) and are named ‘‘best separat-
ing’’ peaks.
3 Results and discussion
3.1 Immunodepletion
The choice of the immunodepletion strategy and MS
conditions represent an essential step required for each test
based on MALDI profiling. The methodological setup for
rhEPO serum profiling, the efficacy and reproducibility of
two commercially available columns developed for human
serum immunodepletion, named MARS Hu7 and Hu14,
derivatized with 6 and 13 antibodies for the most abundant
proteins, was assessed. The MARS Hu7 column permits the
depletion of albumin, IgG, IgA, transferrin, haptoglobin,
antitrypsin, whereas MARS Hu14 column enables the
removal of the same proteins plus a-2-macroglobulin,
a-1-acid glycoprotein, IgM, apolipoprotein AI and AII, C3
complement, and transthyretin. The reproducibility was
assessed by ten serial injections of the same serum sample
and is shown in Supporting Information Fig. 1S. The
protein contents of low-abundant fractions from Hu7 and
Hu14 were 15.3% (SD571.3) and 6.4% (SD571.1),
respectively, in agreement with Bjorhall et al. [17] and
concentration differences correspond to the assumed
amount of the seven depleted proteins by Hu14 [48].
Column specificity is shown in Fig. 1. Crude serum, high-
abundance fractions (HAP Hu7, HAP Hu14) and low-
abundant fractions (LAP Hu7, LAP Hu14) from three serum
samples, pooled after Hu7 and Hu14 immunodepletion,
were analyzed in 15% T SDS-polyacrylamide. Proteins were
visualized by SYPRO Ruby fluorescent staining. A higher
number of bands are visualized using Hu14 immunodeple-
tion, indicating a reduction of the dynamic range. The
attention was focused on the low-abundant fraction which
contains proteins of clinical interest [49]. To accurately
define qualitatively and quantitatively the effects of immu-
nodepletion on serum proteome, a 2-D differential gel
electrophoresis (DIGE) analysis was carried out, being the
sensitivity of this methodology in the order of picograms
[50]. In total, 40 mg of both Hu7 and Hu14 low-abundant
fractions from three pooled samples were labeled with Cy5,
together with the internal standard, labeled with Cy3 and
separated utilizing a 18 cm, pH 3–10 NL gradient, as first
dimension. Each sample was analyzed in triplicate and
image analysis was performed by DeCyder software. Overall,
1419 spots were matched per gel; among them 128 spots
were differentially changed (t-test, po0.01) in Hu14 versus
Hu7 sera.
Figure 2A shows the differences in spot distribution
with same abundance calculated by averaged normalized
volumes Cy5/Cy3, respectively, for Hu7 and Hu14 immu-
nodepleted samples. Hu7 gels contain 12% more spots in
the range 0–1 compared with Hu14. On the contrary, in
Hu14 gels, a general increment in spot distribution, parti-
cularly in the ranges 1–5 and 5–10, was observed, indicating
that the decrement of the dynamic range was associated
with an increment in spot number with higher values of
normalized volumes. Out of 128 spots differentially
expressed, 96 were identified by MS. The identified proteins
together with the average ratio, Student’s t-test p-value, Uni-
Prot KB Entries, theoretical pI, and molecular weights are
listed in Tables 2 and 3 for Hu7 and Hu14 gels, respectively
(Supporting Information Tables 1S and 2S for supporting
data related to MS identifications). Among differentially
changed spots, 16 were strongly decreased in Hu14 gels
with respect to Hu7 as shown in Fig. 2B. In particular,
proteins removed by Hu14 column were identified: four
isoforms of complement component C3 (average ratios of
74.75, 2.08, 86.07, and 22.34, respectively); six
isoforms of a-2-macroglobulin (average ratios equal to –1.5,
1.16, 1.16, 1.36, 1.37, and 1.42 respectively);
a-1-acid glycoprotein 1 (average ratio, –16.64); two isoforms
of apolipoprotein AI (27.74 and 28.64, respectively) and
three isoforms of transthyretin (12.31, 57.88, and
435.39, respectively). As far as concerned a-2-macro-
Figure 1. Representative SDS-PAGE of total serum, MARS Hu7
high-abundance (HAP Hu7), MARS Hu7 low-abundance (LAP
Hu7), MARS Hu14 low-abundance (LAP Hu14), and MARS Hu14
high-abundance (HAP Hu14) fractions. Five micrograms of each
sample were loaded per lane and electrophoresis was carried
out in a discontinuous buffer with a 4% T, 2.5% C stacking gel,
pH 6.8, and a 15% T, 2.5% C, pH 8.8 running gel. The gel was
stained with SYPRO Ruby and scanned at 532 nm excitation with
a 610 nm band pass emission filter with Typhoon laser scanner.
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globulin, the slightly decreased spots could be associated to
protein fragments of the intact protein, with low affinity for
the antibody bound to columns. The intact protein is absent
in our 2-D map. In addition, a clear increment of proteins
usually defined ‘‘scarcely abundant’’ was observed in Hu14
gels respect to Hu7 (Fig. 2C). In particular, eleven spots
with average ratio 43 were detected. The enriched proteins
in Hu14 sample were two isoforms of plasma glutathione
peroxidase (average ratios, 32.77 and 3.47, respectively),
retinol-binding protein 4 (average ratio, 18.59), apolipopro-
tein E precursor (average ratio, 7.62), light chain of factor I
(average ratio, 6.55), and six isoforms of complement factor
B (average ratios equal to 6.03, 5.85, 4.71, 4.3, 3.77, and 3.23,
respectively). Besides, proteins such as kallikrein (two
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Figure 2. (A) The histogram distribution of spots with a certain abundance both after Hu7 and Hu14 depletion. The ranges were
calculated as averaged normalized volumes obtained from the BVA module of DeCyder software. (B) A representative 2-D DIGE gel
image of Cy5-labeled MARS Hu7-depleted serum in which less abundant proteins in Hu14 maps respect to Hu7 are identified and
indicated by circles (reference to Table 2). (C) A representative 2-D DIGE gel image of Cy5-labeled MARS Hu14-depleted serum in which
the identified proteins, more abundant in Hu14 maps respect to Hu7, are indicated (Table 3). In both experiments, 40 mg of protein
mixture was separated in pH 3–10 NL IPG strips in the first dimension until 65 000 VhT, followed by a SDS gel (12% T, 2.5% C) carried out
at 15mA/gel at 201C, O/N. Images were acquired by Typhoon laser scanner, excitation and emission wavelengths were chosen according
to the manufacturer’s recommendations (633 nm laser beam and 670 nm emission filter).
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isoforms 1.28-fold and 1.48-fold increased, respectively) with
a blood concentration at the picomolar level were identified
in Hu14 but not in Hu7 samples. Same spots were detect-
able by DeCyder software but were undetectable by MS
presumably because their abundance in gels was below the
detection limit of the mass spectrometer after gel picking
and in situ digestion. Finally, this analysis highlights
secreted proteins as cytoplasmatic peroxiredoxin 2 (average
ratio, 1.4) and carbonic anhydrase 1 (average ratio, 1.33).
Immunodepleted serum after Hu14 indicates a decrement
of at least one order of magnitude in the dynamic range
which allows to identify proteins at the picomolar level.
3.2 MALDI profiling
The MALDI profiling is based on the assessment of
differences in peak intensities among two or more groups.
The choice of the matrix represents a crucial step and a
number of compounds have been developed for different
applications. Due to their peculiarities, CHCA and DHAP
matrices have been chosen for the proposed experimental
setup for human serum profiling.
Hu7 and Hu14 immunodepleted sera were analyzed
using CHCA and DHAP and an AnchorChip target
was adopted to increment the sensitivity, as suggested
by Leung and Pitts [51]. After immunodepletion, serum
samples were lyophilized and resuspended in 0.1%TFA
at 1 mg/mL concentration. Spectra reproducibility was
assessed by randomly spotting samples to the target, in ten
replicates, to reduce the variability related to a particular
position.
Concerning CHCA, 1 mL of each sample was loaded onto
the MALDI target adopting different sample/matrix ratios and
the best conditions for serum analysis appeared to be the
matrix ratio 1:4 and 1:10. After Hu7 depletion, 111 and 140
peaks were detected, respectively, with an average CV% of 15.4
for 1:4 ratio and 16.5 for 1:10 ratio, whereas Hu14 depletion
provided 120 and 145 peaks for each dilution with an average
CV% of 15 and 13, respectively. Hu7 depletion gives an
increased number of peaks in 1:10 ratio but with a higher
CV% value. Conversely, the sample, depleted using the Hu14
column, shows an increase in both sensitivity and reproduci-
bility. Comparing Hu7 and Hu14 profiles, a peak at m/z
14 000 present in the former disappears in the latter,
suggesting that this signal probably represents one of the
proteins removed by Hu14 column (Fig. 3A and B). This
suggests that CHCA is a suitable matrix for analyzing profiles
up to m/z 15 000 but not above this value. By analyzing
serum, we expect to find a number of small proteins and
peptides released in the blood stream after rhEPO treatment
over m/z 15 000. To increase the range of peak detection
DHAP with different dilutions, different pH and solvent ratios
were investigated. Regarding Hu7-immunodepleted samples,
among different %TFA:sample:matrix ratios, the most
promising appeared at a ratio of 2:2:1 which shows good
sensitivity in the range of m/z 1000–32 000 (a total of 214
peaks were detected with a CV% of 17.4; Supporting Infor-
mation Table 3S), whereas the ratio 1:1:2 provided a good
quality only beyond m/z 5000 (Supporting Information Fig.
2S). Matrix dilution ratios were optimized in parallel for Hu14
immunodepleted sera and the selected conditions were 1:1:1
2% TFA:sample:matrix ratio by which 210 peaks were detec-
ted with a CV% of 18.4 as summarized in Supporting Infor-
mation Table 4S. The differences in peak patterns, related to
the difference in the dynamic range of the applied sample
(Hu7 and Hu14 depleted samples), are shown in Fig. 3C
and D (for the enlarged spectra, see Supporting Information
Table 2. Less abundant proteins in Hu14-depleted sera compared with Hu7 depleted sera
Spot
number
t-Test
p-value
Average ratio VR/VC
(fold change)
Name Swiss-Prot
accession number
Theoretical pI Theoretical
MW (Da)
1 0.000109 22.34 Complement C3 b chain P01024 6.82 71 316.61
2 2.15E05 74.45 Complement C3 b chain P01024 6.82 71 316.61
3 2.85E04 86.07 Complement C3 b chain P01024 6.82 71 316.61
4 1.66E03 1.16 a-2-Macroglobulin P01023 5.98 160 809.88
5 1.28E03 1.37 a-2-Macroglobulin P01023 5.98 160 809.88
6 1.02E03 1.42 a-2-Macroglobulin P01023 5.98 160 809.88
7 1.87E04 2.08 Complement C3 b chain P01024 6.82 71 316.61
8 4.31E03 1.16 a-2-Macroglobulin P01023 5.98 160 809.88
9 9.25E05 1.36 a-2-Macroglobulin P01023 5.98 160 809.88
10 7.05E03 1.50 a-2-Macroglobulin P01023 5.98 160 809.88
11 4.79E04 16.64 a-1-acid Glycoprotein 1 P02763 5.00 21 560.12
12 3.17E06 28.64 Apolipoprotein AI P02647 5.27 28 078.62
13 2.63E06 27.74 Apolipoprotein AI P02647 5.27 28 078.62
14 4.27E06 435.39 Transthyretin precursor P02766 5.52 15 887.03
15 1.95E03 57.88 Transthyretin precursor P02766 5.52 15 887.03
16 8.27E04 12.31 Transthyretin precursor P02766 5.52 15 887.03
Spot number refers to Fig. 2B, Uni-Prot KB entries, name, theoretical pI, and molecular weights are indicated. VR/VC indicates the value
derived from the normalized spot volume standardized against the intragel standard provided by DeCyder software analysis.
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Table 3. More abundant proteins in Hu14-depleted sera compared with Hu7-depleted sera
Spot
number
t-Test
p-value
Average ratio
VR/VC
(fold change)
Name Swiss-Prot
accession
number
Theoretical pI Theoretical
MW (Da)
1 4.50E03 1.27 Ceruloplasmin Q1L857 5.43 115 471.66
2 2.34E02 1.10 Complement component C7 precursor P10643 6.09 93 518.24
3 2.37E03 1.11 Factor H P08603 6.12 137 052.59
4 8.62E03 1.28 Inter-a-trypsin inhibitor heavy chain H4
isoform 2 precursor
B7ZKJ8 6.43 103 880.97
5 5.07E04 1.66 Coagulation factor XII P00748 8.04 67 792.09
6 4.49E03 1.35 Coagulation factor XII P00748 8.04 67 792.09
7 3.05E04 1.55 Coagulation factor XII P00748 8.04 67 792.09
8 2.26E04 1.39 Coagulation factor XII P00748 8.04 67 792.09
9 1.08E03 1.28 Plasma kallikrein precursor P03952 8.60 71 369.69
10 1.96E04 1.25 Chain A. Human complement factor B P00751 6.66 83 000.80
11 5.27E04 1.25 Chain A. Human complement factor B P00751 6.66 83 000.80
12 5.82E03 1.08 Plasma protease C1 inhibitor precursor
variant
P05155 6.09 55 154.19
13 3.22E02 1.14 Vitronectin precursor P04004 5.55 54 305.59
14 3.05E03 2.10 Factor H P08603 6.12 137 052.59
15 2.33E04 4.71 Complement factor B P00751 6.66 83 000.80
16 1.70E04 5.85 Complement factor B P00751 6.66 83 000.80
17 1.46E04 6.03 Complement factor B P00751 6.66 83 000.80
18 1.29E05 4.30 Complement factor B P00751 6.66 83 000.80
19 5.08E03 1.39 a-1-B-glycoprotein P04217 5.63 51 921.66
20 9.70E06 3.77 Complement factor B P00751 6.66 83 000.80
21 3.86E03 1.45 Angiotensinogen P01019 5.60 49 761.11
22 1.80E03 1.45 Complement C1r subcomponent precursor P00736 5.76 78 213.16
23 4.90E02 1.28 Insulin-like growth factor binding protein.
Acid labile subunit
Q8TAY0 6.33 66 067.07
24 2.39E05 3.23 Complement factor B P00751 6.66 83 000.80
25 7.89E04 2.78 Complement factor B P00751 6.66 83 000.80
26 2.45E04 1.40 Hemopexin precursor P02790 6.43 49 295.43
27 6.24E03 1.35 Factor H P08603 6.12 137 052.59
28 1.09E04 1.52 Hemopexin precursor P02790 6.43 49 295.43
29 2.16E03 1.37 C4A protein A6H8M8 6.70 187 703.64
30 1.04E04 1.43 Hemopexin precursor P02790 6.43 49 295.43
31 1.39E03 1.31 C4A protein A6H8M8 6.70 187 703.64
32 4.32E03 1.28 C4A protein A6H8M8 6.70 187 703.64
33 1.72E03 1.23 Hemopexin precursor P02790 6.43 49 295.43
34 9.83E03 1.08 Gelsolin isoform a precursor P06396 5.72 82 959.11
35 6.04E05 1.87 Hemopexin precursor P02790 6.43 49 295.43
36 7.89E03 1.13 Gelsolin isoform a precursor P06396 5.72 82 959.11
37 4.16E04 1.24 Hemopexin precursor P02790 6.43 49 295.43
38 3.62E03 1.30 Vitamin D-binding protein/group-specific
component
P02774 5.40 52 963.65
39 1.45E04 1.40 b-2-Glycoprotein 1 precursor P02749 8.30 38 298.00
40 1.28E04 1.38 b-2-Glycoprotein 1 precursor P02749 8.30 38 298.00
41 1.39E03 1.31 b-2-Glycoprotein 1 precursor P02749 8.30 38 298.00
42 7.29E02 1.15 Complement C4B chain P0C0L5 8.69 71 678.89
43 1.87E04 1.25 b-2-Glycoprotein 1 precursor P02749 8.30 38 298.00
44 8.27E04 1.15 b-2-Glycoprotein 1 precursor P02749 8.30 38 298.00
45 1.02E03 1.34 CFI protein Q8WW88 8.49 42 432.18
46 7.83E04 1.24 CFI protein Q8WW88 8.49 42 432.18
47 3.60E04 1.25 CFI protein Q8WW88 8.49 42 432.18
48 1.24E03 1.21 CFI protein Q8WW88 8.49 42 432.18
49 1.02E03 1.24 Pigment epithelial-differentiating factor P36955 5.90 44 387.80
50 2.32E04 1.12 Complement factor H-related 1 Q03591 7.10 35 738.20
51 2.29E04 1.12 Pigment epithelial-differentiating factor P36955 5.90 44 387.80
52 1.12E03 1.48 Plasma kallikrein B1 precursor P03952 8.60 71 369.69
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Figs. 3S and 4S) where it can be noticed that peaks at m/z
28 000 and at m/z 14 000 values (indicated by arrows) are
present in Hu7 sample but absent in Hu14-immunodepleted
sample. In addition, by comparing profiling from the two
matrices, a peak at m/z 14 000 value was visualized in both
CHCA and DHAP matrices. This will presumably represent
the double-charged specie of an m/z 28 000 peak which is
common to both, low-abundant fractions (LAP) and high-
abundant fractions (HAP) of Hu7 and Hu14, respectively
(Fig. 1). This peak corresponds to apolipoprotein AI (Uni-Prot
KB Entry P02647, MASCOT score 176, coverage 42%)
removed by the Hu14 column and identified after 1-D SDS
PAGE followed by MS. Figure 4 shows Hu14 profiling by
adopting CHCA and DHAP matrices, respectively. DHAP
allows the analysis of a wider m/z range and provides spectra
with a lower background to noise ratio, making it the selected
matrix for our purposes.
In clinical practice, the employment of different speci-
mens (whole blood, serum, or plasma) is strictly related to
the nature of the test; in particular, plasma is utilized
when coagulation factors are of interest. To select the
appropriate specimen for rhEPO monitoring, the efficacy of
the selected conditions was also evaluated in plasma. Plas-
ma profiling was conducted adopting DHAP matrix (ratio,
1:1:1) as shown in Fig. 5. Signals up to m/z 20 000
were detected, and the profile includes 161 peaks with a
CV% of 18.1 but with lower intensity. The presence of high-
abundant coagulation and fibrinolytic components, which
hamper the identification of less abundant species, suggests
that serum is the specimen of choice for applying this
protocol.
3.3 The case of rhEPO treatment
The above-described experimental setup was finalized to the
study of a specific condition: the evaluation of changes in
human serum before and after a low dose (65 IU/Kg) of
rhEPO. Serum samples were collected from ten healthy
young male volunteers, carefully selected, and well-char-
Table 3. Continued
Spot
number
t-Test
p-value
Average ratio
VR/VC
(fold change)
Name Swiss-Prot
accession
number
Theoretical pI Theoretical
MW (Da)
53 5.76E03 1.23 Complement factor H-related 1 Q03591 7.10 35 738.20
54 1.95E02 1.14 Complement factor H-related 1 Q03591 7.10 35 738.20
55 3.74E03 2.74 Apolipoprotein J precursor P10909 5.89 50 062.56
56 9.50E04 2.77 Complement factor H-related 1 Q03591 7.10 35 738.20
57 8.91E05 7.62 Apolipoprotein E precursor P02649 5.52 34 236.68
58 6.60E04 1.93 Complement factor H-related 1 Q03591 7.10 35 738.20
59 8.85E04 3.47 Plasma glutathione peroxidase P22352 8.26 25 402.30
60 3.33E03 1.17 Ficolin-3 isoform 1 precursor O75636 6.20 32 902.98
61 0.0107 1.13 Ficolin-3 isoform 1 precursor O75636 6.20 32 902.98
62 3.07E05 1.89 C4B3 Q6U2L1 5.78 47 454.07
63 2.33E04 1.25 cDNA FLJ55146. Highly similar to
complement C4-B
B4DDH0 6.12 57 513.06
64 2.45E04 1.94 C1q B-chain precursor P02746 8.83 26 721.76
65 0.0231 1.26 Complement component 4A B2RUT6 6.59 192 776.47
66 0.0475 1.16 Complement component 4A B2RUT6 6.59 192 776.47
67 4.58E03 1.24 cDNA FLJ55146. Highly similar to
complement C4-B
B4DDH0 6.12 57 513.06
68 1.34E04 2.79 C1q B-chain precursor P02746 8.83 26 721.76
69 1.23E03 1.38 C1q B-chain precursor P02746 8.83 26 721.76
70 8.85E04 1.41 C1q B-chain precursor P02746 8.83 26 721.76
71 9.98E02 1.11 Complement Factor H-related Protein 2 P36980 5.80 28 738.37
72 2.07E03 1.33 Carbonic anhydrase 1 P00915 6.63 28 739.02
73 6.10E05 1.62 Serum amyloid P component precursor P02743 6.10 25 387.13
74 7.83E04 1.42 Chain B. Globular head of the complement
system protein C1q
P02746 8.85 23 741.92
75 3.58E04 1.35 Serum amyloid P component precursor P02743 6.10 25 387.13
76 1.44E02 1.40 Peroxiredoxin-2 isoform a P32119 5.66 21 891.92
77 1.72E01 1.16 Tetranectin precursor P05452 5.52 22 536.81
78 2.76E04 32.77 Plasma glutathione peroxidase P22352 8.26 25 402.30
79 4.38E04 6.55 Light chain of factor I Q6LAM0 6.24 27 592.38
80 1.44E03 18.59 Retinol binding protein 4 plasma P02753 5.76 23 010.01
VR/VC indicates the value derived from the normalized spot volume standardized against the intragel standard provided by DeCyder
software analysis. Spot number refers to Fig. 2C. Uni-Prot KB entries name, theoretical pI, and molecular weights are indicated.
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acterized subjects. Characteristics of the subjects have been
described previously [42]. By profiling these samples, we
expected to detect the differences related to changes induced
by increased erythropoiesis, hematocrit, hemoglobin, and
iron mobilization, and to propose a new method for
monitoring rhEPO treatment that could be useful for both
clinical purposes and antidoping tests. The time course of
plasma EPO levels (Supporting Information Fig. 5S)
monitored as described previously [42], increased up to
three times in plasma after 6 days of treatment; accordingly,
a similar increment was expected in serum and thus we
focused our attention on samples at day 0 (control samples)
and at day 6, in which EPO reached the maximal
concentration. Both columns, Hu7 and Hu14, were adopted
to verify the effects on the dynamic range of samples treated
with rhEPO, whereas DHAP was the matrix of choice.
Low-abundant fractions from Hu7-immunodepleted
sera were loaded onto a MALDI AnchorChip target as
described previously. Twenty-three differentially changed
peaks (Wilcoxon rank sum test p-valueo0.05) in m/z range
1000–18 000 were obtained and the average sum of spectra
from control and treated sera is shown in Fig. 6A together
with a closeup of a selection of most significant peaks
(Wilcoxon rank sum test p-value o0.05) differentiating the
two cohorts. Unsupervised principal component analysis
(PCA) was unable to discriminate between treated and
untreated sera (Fig. 6B): the score plots did not reveal a
clustering of samples according to the rhEPO treatment. By
utilizing MARS Hu14 column, the LAP fractions were also
analyzed with 1:1:1 2% TFA:sample:matrix in the m/z range
Hu7 column
Hu14 column
CHCA matrix
CHCA matrixA
B
DHAP matrix
DHAP matrix
C
D
Hu7 column
Hu14 column
INT
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m/z2000 10000 18000 26000
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m/z2000 10000 18000 26000
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Figure 3. ClinProTools average spectra for MARS Hu7 (A) and
MARS Hu14 (B) column immunodepleted serum analyzed with
CHCA matrix. Spectra were acquired in linear mode in the m/z
range of 1000–15 000. (C and D) ClinProTools average spectra for
MARS Hu7 and MARS Hu14 column-immunodepleted serum,
respectively, analyzed with DHAP matrix. Spectra were acquired
in linear mode in the m/z range of 1000–32 000. In (C), arrows
indicate the peaks at m/z 14 000 and 28 000 that could refer to
single- and double-charged species of apolipoprotein AI,
respectively. In all cases, each sample was spotted random onto
the AnchorChip target in ten replicates.
Hu14 column,
CHCA matrix
Hu14 column,
DHAP matrix
INT
50
0
50
0
INT
2000 10000 18000 26000
m/z
m/z
2000 10000 18000 26000
Figure 4. ClinProTools average spectra for MARS Hu14-
immunodepleted serum analyzed both with CHCA (1:10
sample/matrix ratio; upper panel) and DHAP matrices (2:2:1,
2 %TFA/sample/matrix ratio; lower panel). Each sample was
randomly spotted onto the AnchorChip target in ten replicates
and spectra were acquired in the m/z range of 1000–32 000.
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1000–32 000. By comparing treated samples versus controls,
186 best separating peaks were detected (Wilcoxon rank
sum test p-value o0.05). The average spectra from controls
and treated sera are shown in Fig. 7A, the closeup refers to
the most significant peaks with a p-valueo0.000001. In this
case, unsupervised PCA could discriminate between classes.
In Fig. 7B, the scores plots indicate a sample’s clusteriza-
tion, suggesting that the selected conditions adopted for
sample preparation and the appropriate matrix and dilutions
allow to discriminate new peptides associated to rhEPO
treatment, opening new perspectives in the use of MALDI
profiling in monitoring rhEPO.
4 Concluding remarks
The effect of serum dynamic range reduction was assessed in
control serum samples, by defining parameters crucial for the
identification of low-abundant species and for the quality of
MALDI profiling analysis. After comparing the enrichment
provided by the two columns, we conclude that the use of
Hu14 allows to enrich less abundant fraction (80 proteins
more represented in LAP), suggesting that immunodepletion
by adopting Hu14 is an efficient and effective reproducible
tool for improving the use of biological fluids for clusterizing
samples, for monitoring disease progression and therapies.
In addition, the identification of secreted proteins
(i.e. peroxiredoxin 2 and carbonic anhydrase 1) further
supports the use of MALDI profiling for monitoring
pathological states that involve release of specific proteins
(largely expressed in organs or tissues like heart, muscles, or
tumors) in the bloodstream, thus broadening the possibility
to identify new biomarkers or to adopt this technology for
profiling changes induced by a specific disease. Moreover, the
identification of proteins present at picomolar level, such as
kallikrein, opens new opportunities in the detection of signal
molecules relevant for clinical diagnosis but undetectable
without the removal of the most abundant species. All these
remarks, when translated in the investigation of proteins and
peptides for monitoring rhEPO treatment in human subjects,
show the efficacy of the proposed setup as supported by the
m/z 4209,23
p-value 0,0118
AUC 0,777902
m/z 7472,04
p-value 0,0118
AUC 0,777902
m/z 7768,71
p-value 0,0118
AUC 0,787946
m/z
A BINT
0
15
30
45
60
75
2000 6000 10000 14000
PC1
PC
2
15
0
-15
0 20 40-20
Figure 6. (A) The average spectra related to
MARS Hu7 LAP fractions from control (red)
and rhEPO-treated subjects (green). Immu-
nodepleted sera were loaded onto the
MALDI AnchorChip target (2 %TFA:sam-
ple:DHAP in the ratio of 2:2:1) and spectra
were analyzed by ClinProTools. Twenty-
three best-separating peaks were observed
(Wilcoxon rank sum test p-value o0.05) in
the m/z range of 1000–18 000 and three out
of them are shown as closeup. (B) The
unsupervised PCA which is unable to
distinguish between groups of the
untreated (red) and treated (green) sera.
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Figure 5. ClinProTools average spectra for serum (upper panel) and
plasma (lower panel) depleted with MARS Hu14 column and
analyzed with DHAP matrix (2:2:1, 2%TFA/sample/matrix ratio).
Each sample was spotted random onto the AnchorChip target in ten
replicates and spectra were acquired in linear mode in them/z range
of 1000–20 000.
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unsupervised PCA. It goes without saying that a careful
subject selection and the control of physiological and
pathological conditions represent a fundamental issue to
put forward the implementation of MALDI profiling for
rhEPOmonitoring in clinical practice. For a prediction model
and validation, a larger number of samples are required;
nevertheless, the proposed setup fulfils the preconditions for
performing clinical investigations adopting high-throughput
technologies. In conclusion, the present results indicate that
the combination of Hu14 column and DHAP matrix by
increasing data quality represents an appropriate approach
for rhEPO serum profiling by MALDI.
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